Choice of regimen is based on :-

• Local cost and availability of antimalarial drugs.
• Area of malaria acquisition (i.e. drug resistance pattern of P. falciparum).
• Prior chemoprophylaxis.
• Known allergies.
• Concomitant illnesses other than malaria.
• Age and pregnancy.
• Likely patient compliance with therapy.
• Risk of re-exposure to malaria after treatment.

In uncomplicated cases in which nausea and vomiting preclude oral therapy, quinine dyhidrochloride 10 mg salt/kg base can be given I.V. in 5% w/v dextrose or normal saline as a 4-hour infusion 8-hourly until the patient can take medication by mouth.

Severe malaria. (where patients have coma, jaundice, renal failure, hypoglycaemia, acidosis, severe anaemia, high parasite count, hyperpyrexia) is ideally treated in an intensive care or high dependency unit where patients can be monitored closely both clinically and biochemically. Intravenous quinine is the treatment of choice but rapid injection can lead to hypotension, dysrhythmias and death.

In patients who have not received quinine in the previous 48 hours, one of two regimens can be used:

1. Quinine dihydrochloride 20 mg salt/kg base given I.V. in 5% w/v dextrose or normal saline as a once-only 4 hour infusion followed, 4 hours later, by quinine dihydrochloride 10 mg salt/kg base 4-hour infusions 8 hourly.
2. Where a syringe pump or other accurate infusion device is available, quinine dihydrochloride 7 mg salt/kg base over 30 minutes followed immediately by quinine dihydrochloride 10 mg salt/kg base over 4 hours then, starting 4 hours later, quinine dihydrochloride 10 mg salt/kg base as 4 hour infusions, 8 hourly.

Electrocardiographic monitoring can be done if available but is not essential unless additional cardiac risks are present.
Where patients have received quinine within the previous 24 hours, give quinine dihydrochloride 10 mg salt/kg base I.V. in 5% w/v dextrose or normal saline as 4-hour infusions, 8-hourly.

P. vivax.
Most strains of P. vivax are still sensitive to chloroquine although some chloroquine resistant strains have been reported in Papua New Guinea, Indonesia, Thailand and India. This drug will clear the erythrocyte stages of the parasite but it has no effect on the exo-erythrocytic liver stage and a course of primaquine (an 8-amino-quinoline) is required for radical cure. The Chesson strain of P. vivax found in New Guinea shows some resistance to primaquine and an increased dose of primaquine is required. If primaquine is not given, the patient may suffer a relapse which will occur weeks or months after the original attack.

Adult treatment.
Based on Chloroquine tablets containing 150mg base.

The primaquine is preferably started after the chloroquine. When the infection is acquired in New Guinea, 3 tablets of primaquine (22.5mg base) should be given daily for 14 days. In the case of a relapse repeat both chloroquine and primaquine treatment. Up to three relapses may occur before the parasite is finally eliminated. Unfortunately there is no other effective treatment. Etaquine is a newly developed long-acting, potent primaquine-like drug which may be available soon for radical cure.

Patients should have their G6PD status checked before primaquine is prescribed. Patients with G6PD deficiency may undergo haemolysis if given a daily dose of primaquine and it is recommended that these patients be given 30-45mg once a week for 8 weeks.

Malarone ^TM may also be used to treat P. vivax malaria but a course of primaquine will still be required to eliminate liver forms.

P. malariae, P. ovale.
Treatment for the eradication of these two strains of malaria is the same as that for P. vivax except it is not necessary to give primaquine to those patients with P. malariae

Artemisinins.

Artemisinin has been used for many years by the Chinese as a traditional treatment for fever and malaria. It is a sesquiterpene lactone derived from Artemisia annua. Because it is being increasingly used in a number of countries and is both cheap and effective it was decided to include treatment schedules here. However, it is not yet licensed for use in Australia, North America or Europe. Its main value at present is in the treatment of multi drug resistant falciparum malaria. If artemisinin is used to treat vivax malaria it should be accompanied by a course of primaquine. Unless used with a second antimalarial as described below there is likely to be a high recrudescent rate. Side effects have been reported but these are comparatively rare and seldom severe. It is recommended only for treatment not for prophylaxis.

Artemisinin (500mg tablets): give 10-20 mg/kg on day 1 (500-1,000 mg) orally then 500mg for 4 days. Then give mefloquine 15mg base/kg or split dose 25mg base/kg.

Artemisinin (200 mg suppositories): for severe malaria 600-1200mg stat, 400-600mg after 4 hours then 400-800mg twice daily for 3 days. Give mefloquine as above.

Artesunate (50 & 60 mg vials for intravenous use): for severe malaria 120mg I.V. stat. 60 mg at 4, 24 and 48 hours, 50-60 mg on days 3-5. Give mefloquine as above.

Dihydroartemisinin (20 mg tablets): first dose 120mg then 60mg daily for 4-6 days then give mefloquine as above.

Artemeter (vials for intramuscular use ): for severe malaria 3.2 mg/kg intramuscularly stat then 1.6mg/kg twice daily for 3-7 days, Give mefloquine as above.

2 Medicines

Prevention

• Chemoprophylaxis
• Mosqutio control For example: Bednets dipping in insecticide.
• Malaria vaccines

Caption: The community plays an important role in the successful use of insecticide-impregnated bednets as a means to combat malaria. Householders in Xuyi County, Jiangsu Province await their turn to dip their nets in deltamethrin.

Epidemiology

World Distribution of Malaria

In China

1. South China-high endemic area: P.f. is prevalent and Mosquito vector: A. mimimus.

2. Central China and Yantze Valley: P.v predominant. Mosquito vector: A. listeri

3. Huang Huai Region: Vector: A.sinensis.

上一页  [1] [2] [3] [4]  下一页